Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer.
Saved in:
| Title: | Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer. |
|---|---|
| Authors: | Kong S; Clinical Pharmacology Modeling and Simulation at Amgen, Thousand Oaks, USA., Minocha M; Clinical Pharmacology Modeling and Simulation at Amgen, Thousand Oaks, USA., Chen PW; Clinical Pharmacology Modeling and Simulation at Amgen, Thousand Oaks, USA., Martinez P; Clinical Development Oncology at Amgen, Thousand Oaks, USA., Anderson ES; Clinical Development Oncology at Amgen, Thousand Oaks, USA., Parkes A; Clinical Development Oncology at Amgen, Thousand Oaks, USA., Houk BE; Clinical Pharmacology Modeling and Simulation at Amgen, Thousand Oaks, USA., Lin CW; Clinical Pharmacology Modeling and Simulation at Amgen, Thousand Oaks, USA. clin04@amgen.com. |
| Source: | Clinical pharmacokinetics [Clin Pharmacokinet] 2025 May; Vol. 64 (5), pp. 729-741. Date of Electronic Publication: 2025 Apr 22. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1179-1926 |
|---|---|
| DOI: | 10.1007/s40262-025-01499-z |
